Data Insights

EVT-801 by Kazia Therapeutics for Pancreatic Cancer: Likelihood of Approval

EVT-801 is under clinical development by Kazia Therapeutics and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - EVT-801 in Pancreatic Cancer

Data Insights

EVT-801 by Kazia Therapeutics for Ovarian Cancer: Likelihood of Approval

EVT-801 is under clinical development by Kazia Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - EVT-801 in Ovarian Cancer

Data Insights

Paxalisib by Kazia Therapeutics for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis): Likelihood of Approval

Paxalisib is under clinical development by Kazia Therapeutics and currently in Phase I for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)....

Data Insights

Paxalisib by Kazia Therapeutics for Gliosarcoma: Likelihood of Approval

Paxalisib is under clinical development by Kazia Therapeutics and currently in Phase III for Gliosarcoma. According to GlobalData, Phase III...

Data Insights

Paxalisib by Kazia Therapeutics for Glioblastoma Multiforme (GBM): Likelihood of Approval

Paxalisib is under clinical development by Kazia Therapeutics and currently in Phase III for Glioblastoma Multiforme (GBM). According to GlobalData,...

Data Insights

Paxalisib by Kazia Therapeutics for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval

Paxalisib is under clinical development by Kazia Therapeutics and currently in Phase III for Recurrent Glioblastoma Multiforme (GBM). According to...

Data Insights

Paxalisib by Kazia Therapeutics for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Paxalisib is under clinical development by Kazia Therapeutics and currently in Phase II for Human Epidermal Growth Factor Receptor 2...

Data Insights

Paxalisib by Kazia Therapeutics for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis): Likelihood of Approval

Paxalisib is under clinical development by Kazia Therapeutics and currently in Phase I for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)....